Welcome to our dedicated page for Terns Pharmaceuticals news (Ticker: TERN), a resource for investors and traders seeking the latest updates and insights on Terns Pharmaceuticals stock.
Terns Pharmaceuticals, Inc. (NASDAQ: TERN) is a clinical-stage biopharmaceutical company advancing novel small molecule therapies for liver diseases, oncology, obesity, and hematologic disorders. This page serves as the definitive source for official company announcements, clinical trial updates, and strategic developments.
Investors and researchers will find timely updates on TERN-701 (chronic myeloid leukemia therapy), metabolic disorder candidates, and regulatory milestones. Our curated news collection includes:
• Clinical trial progress reports
• FDA submission updates
• Research partnership announcements
• Financial results disclosures
All content is sourced directly from company filings and verified press releases. Bookmark this page to monitor Terns' innovative work in molecularly-targeted therapies and capital-efficient drug development.
On October 18, 2021, Terns Pharmaceuticals announced three accepted abstracts for presentation at The Liver Meeting® Digital Experience 2021, focusing on their non-alcoholic steatohepatitis (NASH) programs. Key presentations include:
- TERN-101: Favorable safety and efficacy from the Phase 2a LIFT Study.
- TERN-501: Well-tolerated in first-in-human trials, showing dose-dependent cholesterol changes.
These findings underscore Terns' commitment to developing effective therapies for chronic liver diseases.
Terns Pharmaceuticals, a clinical-stage biopharmaceutical company, announced its participation in the H.C. Wainwright 5th Annual NASH Investor Conference set for October 12, 2021, at 2:30 p.m. ET. The company is focused on developing therapies for non-alcoholic steatohepatitis (NASH) and chronic liver diseases, featuring a portfolio that includes three clinical-stage programs and a preclinical program. A live audio webcast of the presentation will be available on Terns’ investor relations page, with a replay archived for 30 days.
Terns Pharmaceuticals has appointed Dr. Ann E. Taylor to its Board of Directors. With over 35 years in drug development, including her tenure as Chief Medical Officer at AstraZeneca, Dr. Taylor is expected to bring valuable expertise to Terns, particularly in developing treatments for non-alcoholic steatohepatitis (NASH) and chronic liver diseases. Terns is known for its innovative therapeutic approaches, including a diverse pipeline featuring small-molecule therapies aimed at addressing NASH.
Terns Pharmaceuticals has completed patient enrollment for Part 1 of the AVIATION Trial, a Phase 1b study for TERN-201, a selective VAP-1 inhibitor targeting chronic liver inflammation and fibrosis in NASH patients. Preliminary top-line data is expected in 1Q 2022. The trial aims to assess the safety and tolerability of TERN-201 in comparison to a placebo over 12 weeks. TERN-201 has shown promise in preclinical studies, and the company received FDA Fast Track Designation for the treatment of NASH.
Terns Pharmaceuticals, a clinical-stage biopharmaceutical company focused on therapies for non-alcoholic steatohepatitis (NASH), announced upcoming presentations at key investor conferences in September 2021. The conferences include the 2021 Virtual Wells Fargo Healthcare Conference on September 9, the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, and the Oppenheimer Fall Healthcare Summit on September 20. Investors can access live webcasts on Terns' investor relations page, with replays available for 30 days.
Terns Pharmaceuticals reported financial results for Q2 2021, achieving significant clinical milestones in its NASH pipeline. The company initiated the Phase 1b AVIATION Trial for TERN-201 and completed a multiple ascending dose portion of the TERN-501 trial. Cash reserves are strong at $185.1 million, projected to last until 2024. Top-line data from TERN-501 is expected in 4Q 2021 and from TERN-201 in 1H 2022. Despite a net loss of $10.7 million for the quarter, decreased R&D expenses show a positive trend for operating efficiency.
Terns Pharmaceuticals, Inc. (Nasdaq: TERN), a clinical-stage biopharmaceutical company, has announced its participation in two key healthcare conferences. Management will join a liver disease panel at the 2021 Wedbush PacGrow Healthcare Conference on August 10 at 2:20 PM ET. Additionally, Terns will present at the Canaccord Genuity 41st Annual Growth Conference on August 11 at 1:00 PM ET. Both events will be available via live webcast on Terns' investor relations page, with replays accessible for 30 days post-presentation.
Terns Pharmaceuticals initiated patient dosing for the AVIATION Trial, a Phase 1b study evaluating TERN-201, a selective VAP-1 inhibitor targeting chronic liver inflammation and fibrosis in NASH. This trial aims to assess the safety and efficacy of TERN-201 over a 12-week period, with preliminary data expected in 2022. TERN-201 demonstrated well-tolerated results in prior studies, showing significant potential in reducing liver inflammation. The drug's selective inhibition may complement other therapies in Terns’ portfolio.
Terns Pharmaceuticals reported positive results from the Phase 2a LIFT clinical trial of TERN-101, an FXR agonist for NASH treatment. The trial demonstrated no discontinuations due to adverse events, including pruritus, and significant improvements in corrected T1 (cT1), a liver inflammation and fibrosis marker. After 12 weeks, significant changes in cT1 were observed in the 10 mg and 15 mg groups compared to placebo. Terns plans a combination trial of TERN-101 with TERN-501 in early 2022, following these promising outcomes.
Terns Pharmaceuticals, Inc. (Nasdaq: TERN) announced a conference call to discuss new top-line data from the Phase 2a LIFT study evaluating TERN-101 in patients with non-alcoholic steatohepatitis (NASH). The call is scheduled for June 14, 2021, at 8:30 a.m. ET, with a live webcast available. Terns focuses on developing small-molecule therapies targeting NASH and chronic liver diseases, aiming to offer significant clinical benefits based on validated mechanisms of action. The details of the webcast and conference call are provided for interested stakeholders.
